Study of Rituximab Plus High-Dose Chemotherapy Non-Hodgkin's Lymphoma
Status:
Completed
Trial end date:
2007-01-01
Target enrollment:
Participant gender:
Summary
This study is being conducted to determine the safety, side effects, and response to a
combination of an established high-dose chemotherapy regimen, plus the addition of Rituximab
(which is a form of immunotherapy).
Phase:
Phase 2
Details
Lead Sponsor:
University of Michigan Cancer Center University of Michigan Rogel Cancer Center